2026 Safety Guide
NAD+ Side Effects
Complete NAD+ safety profile: reported side effects from published research, contraindications, severity tiers, and how to minimize adverse reactions through proper dosing and vendor selection.
Reported NAD+ side effects
Nicotinamide Riboside (NR) NR has the best-characterized safety profile of the NAD+ precursors. Across published RCTs at 1,000-2,000 mg/day for up to 12 weeks, adverse effects have been mild and uncommon: Gastrointestinal upset (5-10% of users) Mild headache Fatigue or drowsiness (uncommon) Insomnia if dosed late in the day No serious adverse events have been reported in pooled analyses. Nicotinamide Mononucleotide (NMN) NMN safety data is more limited than NR but reassuring in published trials: Similar GI upset profile to NR Mild flushing or warmth at higher doses (uncommon) Single-dose studies up to 500 mg well-tolerated; longer-term 250-900 mg daily studies have not identified concerning signals Nicotinamide (NAM) Broad safety at typical doses (250-1,500 mg/day). Key concerns at higher doses: Methyl-group consumption: NAM is metabolized by NNMT using S-adenosylmethionine (SAM) as methyl donor; chronic high NAM doses may deplete methylation substrate if dietary methyl donors (folate, B12, choline, betaine) are inadequate Hepatotoxicity: rare but documented at doses >3,000 mg/day Sirtuin inhibition paradox: NAM is a weak direct inhibitor of sirtuins at very high concentrations (in vitro); whether this matters at physiologic dietary doses is uncertain Nicotinic Acid (NA / Niacin) Cutaneous flushing: prostaglandin D2-mediated, dose-dependent, resolves with continued use. Extended-release formulations reduce flushing. Hepatotoxicity: extended-release formulations have greater hepatic toxicity risk than immediate-release Hyperglycemia: high-dose niacin worsens glucose tolerance; caution in diabetes Hyperuricemia: may precipitate gout IV NAD+ Chest pressure or tightness during infusion (dose-dependent; slow infusion rate reduces this) Flushing or warmth during infusion Nausea or vomiting if infused too rapidly Headache post-infusion (common, 15-25%) These effects almost universally resolve with slower infusion rates; typical protocols infuse 500-1,500 mg over 2-4 hours. Theoretical concerns across NAD+ precursors: Cancer progression: NAD+ fuels PARP-mediated DNA repair, which could theoretically support tumor cell survival under chemotherapy stress. Some preclinical data supports and some refutes this concern. Caution during active cancer treatment and discussion with oncology team is prudent. Insomnia from late-day dosing: avoid dosing after 3 PM if sleep sensitivity occurs
When to continue, reduce, or stop NAD+
Mild: continue protocol
Transient mild symptoms (slight GI upset, minor injection-site reaction, brief fatigue) typically resolve within 3-7 days as physiology adjusts. Continue at current dose; monitor weekly.
Moderate: reduce dose
Persistent mild symptoms past two weeks, or new symptoms like sustained mood changes, sleep disruption, or appetite shifts. Reduce dose by 25-50% and reassess at the end of the next 2-week window.
Severe: discontinue + seek care
Any signal of allergic response (rash, swelling, breathing difficulty), unexplained chest discomfort, severe injection-site reaction with infection signs, or vision changes. Discontinue immediately and consult a licensed practitioner.
NAD+ contraindications
Absolute contraindications (systemic NAD+ precursor use) Active malignancy under treatment — discuss with oncology team; theoretical concern about NAD+ supporting tumor DNA repair during chemotherapy stress Known hypersensitivity to the specific formulation Pregnancy and breastfeeding — no safety data for elevated-dose supplementation beyond dietary adequacy Relative contraindications Peptic ulcer disease — high-dose niacin specifically can worsen; NR/NMN less concerning Active gout or significant hyperuricemia — high-dose niacin risk; NR/NMN less concerning Uncontrolled diabetes — niacin worsens glucose; NR/NMN may improve glucose (Yoshino 2021) Severe hepatic impairment — hepatic NAD+ metabolism may be impaired Concurrent anti-seizure medications (valproate) — methyl donor interactions with NAM specifically IV NAD+ specific contraindications Severe cardiovascular disease or unstable angina (chest tightness during infusion) Active psychosis or severe anxiety disorder Pregnancy Active substance withdrawal without medical supervision Regulatory status NR: Generally Recognized As Safe (GRAS) in the US; legal dietary ingredient in EU, UK, Canada, Australia NMN: FDA wrote in October 2022 that NMN was excluded from the US dietary supplement definition. On 29 September 2025, in its response to citizen petition FDA-2023-P-0872, FDA concluded that NMN is not excluded, because NMN was sold as a dietary supplement in the US as early as 2017, before it was authorized for investigation as a drug. Status outside the US varies by country. NAM (nicotinamide): legal dietary supplement worldwide NA (nicotinic acid / niacin): legal dietary supplement; prescription formulations exist for lipid indications IV NAD+: compounded by 503A pharmacies for specific patients; not FDA-approved as a drug product WADA: NAD+ precursors are not specifically prohibited for athletes; dietary supplement status applies.
Why vendor quality drives NAD+ side-effect frequency
Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.
Full NAD+ profile
Mechanism, dosing, half-life, peer-reviewed studies.
NAD+ protocol
Three-tier dosing protocol with cycle structure.
Alternatives
If side-effect profile rules out NAD+ for you, similar compounds.
NAD+ side effects FAQ
What are the most common NAD+ side effects?
Nicotinamide Riboside (NR) NR has the best-characterized safety profile of the NAD+ precursors. Across published RCTs at 1,000-2,000 mg/day for up to 12 weeks, adverse effects have been mild and uncommon: Gastrointestinal upset (5-10% of users) Mild headache Fatigue or drowsiness (uncommon) Insomnia if dosed late in the day No serious adverse events have been reported in pooled analyses. Nicotinam
Are there severe side effects to watch for with NAD+?
Severe reactions are rare in published research but can occur. Watch for: allergic-type symptoms (rash, swelling, breathing difficulty), unexplained chest discomfort, infection signs at injection sites, vision changes, or severe persistent mood/sleep disruption. Any of these warrants immediate discontinuation and consultation with a licensed practitioner. The Severity Tiers section above triages mild → moderate → severe response patterns.
Does NAD+ have contraindications?
Absolute contraindications (systemic NAD+ precursor use) Active malignancy under treatment — discuss with oncology team; theoretical concern about NAD+ supporting tumor DNA repair during chemotherapy stress Known hypersensitivity to the specific formulation Pregnancy and breastfeeding — no safety data for elevated-dose supplementation beyond dietary adequacy Relative contraindications Peptic ulcer
How can I minimize NAD+ side effects?
Three biggest levers: (1) Start at the Beginner-tier dose for 2-3 weeks before escalating, which gives time to detect adverse signals at minimum effective dose. (2) Source from COA-verified vendors only: impurity profiles and mislabeled compounds drive a disproportionate share of reported side effects in research-compound communities. (3) Maintain adequate cycle off-time when applicable: receptor-saturating compounds benefit from 4-6 week breaks. The vendor section below lists the cheapest in-stock NAD+ sources we track, each linked to its Trust Score (COA verification is 30% of the score).
Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.